GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PEPTONIC medical AB (XSAT:PMED) » Definitions » EV-to-Revenue

PEPTONIC medical AB (XSAT:PMED) EV-to-Revenue : 0.87 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PEPTONIC medical AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PEPTONIC medical AB's enterprise value is kr34.05 Mil. PEPTONIC medical AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr39.05 Mil. Therefore, PEPTONIC medical AB's EV-to-Revenue for today is 0.87.

The historical rank and industry rank for PEPTONIC medical AB's EV-to-Revenue or its related term are showing as below:

XSAT:PMED' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.86   Med: 5.7   Max: 589.44
Current: 0.87

During the past 11 years, the highest EV-to-Revenue of PEPTONIC medical AB was 589.44. The lowest was 0.86. And the median was 5.70.

XSAT:PMED's EV-to-Revenue is ranked better than
81.86% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 2.275 vs XSAT:PMED: 0.87

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-08), PEPTONIC medical AB's stock price is kr0.0102. PEPTONIC medical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.03. Therefore, PEPTONIC medical AB's PS Ratio for today is 0.39.


PEPTONIC medical AB EV-to-Revenue Historical Data

The historical data trend for PEPTONIC medical AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PEPTONIC medical AB EV-to-Revenue Chart

PEPTONIC medical AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.07 13.27 3.95 1.18 2.23

PEPTONIC medical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.72 2.04 2.23 2.08

Competitive Comparison of PEPTONIC medical AB's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, PEPTONIC medical AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PEPTONIC medical AB's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PEPTONIC medical AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where PEPTONIC medical AB's EV-to-Revenue falls into.



PEPTONIC medical AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

PEPTONIC medical AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=34.047/39.051
=0.87

PEPTONIC medical AB's current Enterprise Value is kr34.05 Mil.
PEPTONIC medical AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr39.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PEPTONIC medical AB  (XSAT:PMED) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

PEPTONIC medical AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0102/0.026
=0.39

PEPTONIC medical AB's share price for today is kr0.0102.
PEPTONIC medical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PEPTONIC medical AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of PEPTONIC medical AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PEPTONIC medical AB (XSAT:PMED) Business Description

Traded in Other Exchanges
Address
Gustavslundsvägen 143, Bromma, SWE, SE-167 51
PEPTONIC medical AB is a pharmaceutical company. It is engaged in developing oxytocin-based products for the treatment of menopausal symptoms, such as vaginal atrophy and vaginal dryness. Oxytocin is for medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. The company is based in Sweden.

PEPTONIC medical AB (XSAT:PMED) Headlines

No Headlines